Home / Centerstage / 2026 / april / Week 2 /
Revolution Medicines reports landmark Phase 3 results on April 13, 2026, for its oral drug daraxonrasib (RMC-6236), offering new hope for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Affecting around 250,000 to 300,000 people globally each year, PDAC has long had one of the lowest survival rates in oncology. The RASolute 302 trial is being hailed by oncologists as a potential “game changer,” signaling a major breakthrough in treatment and improving prospects for patients facing this aggressive cancer.
Monday, 13 April, 2026